Longo, M.; Paolini, E.; Di Benedetto, P.; Tomassini, E.; Meroni, M.; Dongiovanni, P.
DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application. Int. J. Mol. Sci. 2024, 25, 9074.
https://doi.org/10.3390/ijms25169074
AMA Style
Longo M, Paolini E, Di Benedetto P, Tomassini E, Meroni M, Dongiovanni P.
DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application. International Journal of Molecular Sciences. 2024; 25(16):9074.
https://doi.org/10.3390/ijms25169074
Chicago/Turabian Style
Longo, Miriam, Erika Paolini, Pietro Di Benedetto, Elena Tomassini, Marica Meroni, and Paola Dongiovanni.
2024. "DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application" International Journal of Molecular Sciences 25, no. 16: 9074.
https://doi.org/10.3390/ijms25169074
APA Style
Longo, M., Paolini, E., Di Benedetto, P., Tomassini, E., Meroni, M., & Dongiovanni, P.
(2024). DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application. International Journal of Molecular Sciences, 25(16), 9074.
https://doi.org/10.3390/ijms25169074
